[Ip-health] Pharma to "tour" BRICs

Rachel Kiddell-Monroe rachel.kiddellmonroe at gmail.com
Tue Apr 5 06:29:14 PDT 2011


Eli Lilly To Start Global Service Program.

The *AP*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=013-251&t=c>(3/31)
reported, "Eli Lilly and Co. is starting a service program that sends
employees around the world to help developing communities and learn about
other cultures, as the drugmaker looks to international markets to help
counter expected sales losses from patent expirations for key products."
Lilly said it will send "groups of eight or nine employees on 23 two-week
trips this year, starting Saturday in New Delhi, India." Other countries on
the program's travel schedule include Brazil, China and Russia. The
employees will help with "healthcare, teaching and caregiving for the
elderly and infants," among other activities.
 Some Religious Groups Pressing Pharma Companies To Ease Up On Price
Increases.

The *Wall Street
Journal*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=014-759&t=c>(4/1,
Loftus) reports that some religious groups are putting pressure on
major pharmaceutical companies to refrain from making steep price increases.
Groups, such as the Sisters of Charity, have placed shareholder proposals on
the ballots for forthcoming annual meetings by Pfizer, Johnson & Johnson,
Bristol-Myers Squibb and Abbott Laboratories, urging the drugmakers to adopt
price-restraint measure for branded drugs.


On Fri, Apr 1, 2011 at 7:56 AM, DIA Daily
<DIADaily at dia.custombriefings.com>wrote:

> *If you are using a mobile device or are unable to see the message below, click
> here to view<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e>
> *     [image: Please add DIADaily at dia.custombriefings.com to your address
> book]
> <http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=000-66c&t=c>   Customized
> Briefing for Karolina Maciag April 1, 2011      Leading the News
> <#12f25d74fe6e0857_12f20efadd15908f_12f10ec55594f90e_SLeading_the_Ne>
>  Drug Research
> <#12f25d74fe6e0857_12f20efadd15908f_12f10ec55594f90e_SDrug_Research>
>   Clinical Research
> <#12f25d74fe6e0857_12f20efadd15908f_12f10ec55594f90e_SClinical_Resea>
>  Business of Medicine
> <#12f25d74fe6e0857_12f20efadd15908f_12f10ec55594f90e_SBusiness_of_Me>
>   Also in the News
> <#12f25d74fe6e0857_12f20efadd15908f_12f10ec55594f90e_SAlso_in_the_Ne>
> DIA Career Center<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=001-05c&t=c>    Leading the News
>   [image: Advertisement]<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=002-2ed&t=c>  Cost-Cutting
> Measures By Drug Companies Could Lead To Less R&D.
>
> In an article titled "When Prescription Drugs Don't Work," *Reuters*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=003-d82&t=c>(4/1) reports that antibiotics can kill a wide range of microbes because the
> drugs are given in the first 48 hours when doctors are still trying to
> figure out exactly which microbe caused the illness. The article adds that
> in recent years drug companies are using cost-cutting plans to close
> laboratories and are seeing declining returns on research and development.
> Notably, Food and Drug Administration Commissioner Margaret Hamburg said at
> the National Press Club, "We need new and better drugs- and we need them
> now. Yet the R&D pipeline is distressingly low."
>
>         In another article, *Reuters*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=004-288&t=c>(3/31) reported that antibiotics are not profitable for drug companies
> because people who are ill only use antibiotics for several days and in
> small quantities. Yet, drug companies like patients who use cholesterol and
> heart medicine because those drugs will be used over the course of a
> lifetime. Notably, in the past five years, the demand for prescription drugs
> has increased by 40 percent. But, during the same period antibiotics sales
> declined to $14.4 billion from $16.1 billion. Notably, health industry
> expert David Shlaes in writing to Health and Human Services Secretary
> Kathleen Sebelius said that regulators, such as the FDA, are part of the
> problem.
>     From DIA
>
> Our calendar of upcoming international educational offerings includes:
>
>    - Calls for Abstracts<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=005-8c2&t=c>:
>    *Due April 1* for Dried Blood Spot Sampling in the Pharmaceutical
>    Industry: Three Years of Experience & Implementation<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=006-7c3&t=c>
>    - *Due May 16* for DIA Canadian Annual Meeting 2011: New Models, New
>    Frameworks, New Partnerships<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=007-a70&t=c>
>    - Quest for Quality: The Changing Regulatory Landscape<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=008-da1&t=c>,
>    April 7-9 in Ahmedabad, India
>    - 3rd Annual Latin American Regulatory Conference: Harmonization of
>    Regulatory Requirements in Drug Development & Registration<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=009-8fc&t=c>,
>    April 12-15 in Panama City, Panama
>    - Asia Regulatory Conference: Asia's Role in Global Drug Development<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=00a-747&t=c>,
>    April 26-28 in Seoul, Republic of Korea
>    - 5th Annual Conference in Japan for Asian New Drug Development<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=00b-9d4&t=c>,
>    May 10-11, in Tokyo
>    - 3rd DIA China Annual Meeting: Quality & Standards: Elevating China
>    Pharmaceutical Development<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=00c-562&t=c>,
>    May 16-18 in Beijing
>    - 2nd DIA Cardiac Safety Workshop in Japan<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=00d-da1&t=c>,
>    June 1-2, in Tokyo
>
>     Drug Research
>   [image: Advertisement]<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=00e-2f3&t=c>  Knee-Surgery
> Drug Fails To Meet Late-Stage Clinical Trial Goals.
>
> The *AP*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=00f-eae&t=c>(4/1) reports that Omeros said on Thursday "that its experimental knee drug
> did not meet goals of a late-stage clinical trial. Omeros said it couldn't
> draw any conclusions about the drug's effectiveness in the study because of
> 'confounding factors,' or variables that made it impossible to tell if its
> drug was responsible for changes in the condition of patients." The company
> was testing "OMS103HP in patients undergoing arthroscopic surgery to
> reconstruct" an anterior cruciate ligament (ACL). The drug was developed to
> "improve joint motion and reduce pain" after surgery. *Dow Jones Newswire*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=010-d5b&t=c>(4/1, FitzGerald) and
> *Reuters*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=011-c55&t=c>(4/1, Jain, Basu) also cover the trial results.
>  Potential Hepatitis C Treatment Meets Mid-Stage Trial Safety,
> Tolerability Goals.
>
> The *AP*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=012-42b&t=c>(3/31) reported "Vertex Pharmaceuticals Inc. said Thursday that a potential
> hepatitis C treatment was safe and tolerable in a midstage" trial. "The
> study involved a combination of telaprevir and VX-222 with
> pegylated-interferon and ribavirin and focused on people with genotype 1
> chronic hepatitis C who were new to treatment."
>   Clinical Research
>  Indiana-Based Clinical Trial Involves Using Alcoholism Medicine To Treat
> Autism.
>
> A "Healthbeat" segment appearing on *WTHR-TV* Indianapolis (3/31, 5:22
> p.m. EDT) reported that Dr. Craig Erickson, chief of the Riley Hospital for
> Children Christian Sarkine Autism Treatment Center, has begun a trial using
> acamprosate, an FDA-approved medication for the treatment of alcoholism, to
> treat patients with the form of autism known as Fragile X Syndrome (FXS).
> Dr. Erickson said he got the idea from reading medical journals. "Chronic
> alcohol use causes a brain injury with certain chemical systems in the brain
> similar to the chemical abnormalities in Fragile X animal models, so in that
> sense the deficits show some potential overlap," he said. Doctors say the
> clinical improvements are promising, which is why IU Health is expanding the
> study.
>   Business of Medicine
>  Eli Lilly To Start Global Service Program.
>
> The *AP*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=013-251&t=c>(3/31) reported, "Eli Lilly and Co. is starting a service program that sends
> employees around the world to help developing communities and learn about
> other cultures, as the drugmaker looks to international markets to help
> counter expected sales losses from patent expirations for key products."
> Lilly said it will send "groups of eight or nine employees on 23 two-week
> trips this year, starting Saturday in New Delhi, India." Other countries on
> the program's travel schedule include Brazil, China and Russia. The
> employees will help with "healthcare, teaching and caregiving for the
> elderly and infants," among other activities.
>  Some Religious Groups Pressing Pharma Companies To Ease Up On Price
> Increases.
>
> The *Wall Street Journal*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=014-759&t=c>(4/1, Loftus) reports that some religious groups are putting pressure on
> major pharmaceutical companies to refrain from making steep price increases.
> Groups, such as the Sisters of Charity, have placed shareholder proposals on
> the ballots for forthcoming annual meetings by Pfizer, Johnson & Johnson,
> Bristol-Myers Squibb and Abbott Laboratories, urging the drugmakers to adopt
> price-restraint measure for branded drugs.
>  Japan's Nuclear Crisis Sparks New Urgency For Radiation Drugs.
>
> On the front page of its Business Day section, the *New York Times*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=015-d6f&t=c>(4/1, B1, Pollack) reports, Japan's "crisis has put a spotlight on some
> small biotechnology companies developing drugs to treat people exposed to
> radiation," many of the companies accelerating their efforts. Most of the
> companies are "working under contracts from the US government, aimed at
> treating people after a military or terrorist attack involving a nuclear or
> radioactive weapon." They want to "make their drugs available for use in
> Japan, but the government there has not ordered any." Moreover, the drugs
> "have not been approved by the Food and Drug Administration." Most of the
> drugs are "two to five years away from possible" approval; and even once
> approved "there would still be some slight uncertainty about how well they
> would work in people," FDA officials say.
>
>         Metro Atlantans Want To Stockpile Anti-Radiation Drug. The *Atlanta
> Journal-Constitution*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=016-5ef&t=c>(3/31, Schneider) noted that "anxious metro Atlantans have joined the hunt
> for potassium iodide tablets...but supplies are scarce, and experts say
> Georgians are not at risk from the nuclear crisis in Japan." The Centers for
> Disease Control and Prevention is "telling people not to consume potassium
> iodide tabs." Moreover, radiation expert Dr. Walter Curran, executive
> director of the Winship Cancer Institute at Emory University "cautioned
> against storing the drug in a household medicine cabinet where curious
> youngsters could get hold" of a drug whose side effects include "permanent
> thyroid damage. ... 'It would be better for all of us to have rattlesnake
> kits in our homes than potassium iodide,'" Dr. Curran said.
>  GlaxoSmithKline, Pfizer Disclose Fees Paid To US Physicians.
>
> The *Wall Street Journal*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=017-979&t=c>(4/1, Loftus) reports that in 2010, GlaxoSmithKline PLC paid $85 million to
> US physicians and institutions for their work on clinical trials,
> consulting, speaking and other services. The *AP*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=018-1ec&t=c>(4/1) reports, Pfizer Inc. "said Thursday it spent $177 million in 2010 on
> payments to doctors and other healthcare professionals for a mix of
> research, speeches, and other services."
>   Also in the News
>  German Medical Association Advises Physicians To Give Out More Placebos.
>
> The *AP*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=019-fba&t=c>(3/31, Cheng) reported, "After completing a major study on the use of
> placebos, the German Medical Association recently concluded the fake pills
> sometimes work better than real medicines and recommended that doctors give
> them out more often -- even without explicitly telling their patients." Dr.
> Peter Scriba, chairman of the German Medical Association's advisory board,
> said that "placebos could help patients with mild anxiety, depression,
> chronic inflammatory problems, pain and asthma." Dr. Scriba said that
> "placebos shouldn't be used for conditions where an effective therapy exists
> and that doctors must tell patients they're getting something unusual."
> However, he said physicians are under no obligation to actually use the word
> "placebo."
>  Adequate Vaccination, Wound Treatment Could Reduce Rare But Deadly
> Tetanus Disease In US.
>
> *MedPage Today*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=01a-7be&t=c>(3/31, Fiore) reported, "Although rare, tetanus is still a life-threatening
> disease in the US, largely because of inadequate vaccination and wound care
> prophylaxis," according to a *study*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=01b-d3b&t=c>in the Centers for Disease Control and Prevention's Morbidity and Mortality
> Weekly Report. The researchers analyzed data from the National Notifiable
> Diseases Surveillance System (NNDSS) "between 2001 and 2008," and found "a
> total of 233 cases of tetanus."
>
>         *HealthDay*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=01c-51f&t=c>(3/31, Preidt) reported, "The death rate was 13.2 percent in the 197 cases
> with known outcomes," the CDC said. The risk of death was highest "among
> people older than 65, diabetics, and those who hadn't been vaccinated or
> didn't have up-to-date vaccinations." According to the researchers,
> "vaccination can prevent tetanus, and healthcare providers should ensure
> that all their patients, especially those older than 65 and those with
> diabetes, have up-to-date vaccinations."
>  Georgia House Approves Prescription Medication Database Measure.
>
> The *Atlanta Journal-Constitution*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=01d-e31&t=c>(4/1, Hunt) reports, "Physicians and pharmacists can review their patients'
> prescription history -- one way to see if they are addicts or drug dealers
> -- under a database approved Thursday by the Georgia House. The Senate
> already approved the bill (SB 36) that requires pharmacists and doctors who
> dispense medicines to report to the state weekly on who receives
> prescriptions for a broad spectrum of potentially addictive drugs."
> Opponents were "not comforted by criminal penalties for those who
> negligently use the database or release information from it, arguing that
> patient privacy is at stake."
>  Administration Unveils New Rules For ACOs.
>
> The *New York Times*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=01e-c51&t=c>(4/1, A20, Pear) reports, "The Obama administration proposed long-awaited
> *regulations*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=01f-870&t=c>on Thursday encouraging doctors and hospitals to band together, coordinate
> care and cut costs. In return, the government offered financial rewards to
> healthcare providers that slow spending growth and meet detailed federal
> standards for the quality of their services."
>
>         The *Wall Street Journal*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=020-675&t=c>(4/1, Johnson) reports that under the new rules, physicians and hospitals
> would form groups called accountable care organizations, or ACOs, which are
> intended to help coordinate care in the Medicare system. At present,
> Medicare patients see several specialists, who do not typically communicate
> with each other about the care being provided, leading to higher costs and
> poor quality. The ACOs are meant to change that. Commenting on the rules,
> HHS Secretary Kathleen Sebelius said, "We need to bring the days of
> fragmented care to an end."
>
>         *USA Today*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=021-64a&t=c>(4/1, Kennedy) reports that, in fact, ACOs "could save Medicare $960 million
> over the next three years, Health and Human Services Secretary Kathleen
> Sebelius said." She also underscored "the need for preventive care, saying
> that 1 in 5 Medicare patients who make a visit to the hospital are back
> within 30 days, and that 1 in 7 suffer a harmful mistake. Another 100,000
> patients die from infections every year."
>
>         The *AP*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=022-b0f&t=c>(4/1) reports, "Eagerly awaited by the healthcare industry, the new approach
> was called for in President Barack Obama's healthcare overhaul." Should it
> prove successful "in Medicare, it is expected spread quickly to
> employer-provided health insurance." In some parts of the US, "such as the
> Minneapolis area, insurers, hospitals and doctors have set up similar
> networks for privately insured patients." But, certain experts warn that
> ACOs "could end up costing more money because of the intensive work involved
> in coordinating among different providers."
>
>         The *Washington Post*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=023-331&t=c>(4/1, Goldstein) explains, "Unlike in Medicare Advantage, the managed-care
> part of Medicare, patients will not sign up for an ACO." Rather, "they will
> be assigned to one at the end of each year if the doctor they see most often
> for primary care is part of such a group." Physicians "who participate in an
> ACO must post signs and tell their patients."
>
>         The *Los Angeles Times*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=024-e1f&t=c>(4/1, Levey) reports, "The Obama administration hopes many of the more than
> 45 million seniors and others who rely on Medicare will ultimately get their
> care this way; the administration's early estimates are that about 1.5
> million to 4 million people would participate by 2014."
>
>         Also covering the story are *Reuters*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=025-26a&t=c>(4/1),
> *Bloomberg News*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=026-06e&t=c>(4/1, Wayne),
> *The Hill*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=027-427&t=c>(4/1, Pecquet) "Healthwatch" blog, Ezra Klein in his
> *Washington Post*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=028-696&t=c>(4/1) blog,
> *NPR*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=029-902&t=c>(4/1, Galewitz, Gold) "Shots" blog,
> *National Journal*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=02a-e18&t=c>(4/1, McCarthy),
> *CQ HealthBeat*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=02b-73d&t=c>(4/1, Reichard), the
> *Palm Beach Post (FL)*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=02c-478&t=c>(4/1, Singer),
> *Modern Healthcare*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=02d-208&t=c>(4/1, Zigmond),
> *McClatchy*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=02e-56a&t=c>/Kaiser Health News (4/1, Galewitz, Rau, Vaida),
> *American Medical News*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=02f-faf&t=c>(4/1, Fiegl), the
> *Hartford Courant*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=030-eb8&t=c>(4/1, Sturdevant) and
> *Government Health IT*<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=031-2a3&t=c>(4/1, Manos).
>    Subscriber Tools
>      • Unsubscribe<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=032-d1f&t=c>
>      • Change Email Address <Changeofaddress at diahome.org>
>      • Send Feedback <+feedback at diahome.org?subject=DIA+Daily+Feedback>
>      • Email Help<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=034-1eb&t=c>
>      • Archives<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=035-965&t=c>
>  Advertise with DIA Daily: Reach key professionals every day
> <http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=036-66b&t=c>
>
> DIA Daily is a digest of the most important news selected from thousands of
> sources by the editors of Custom Briefings. The presence of content or
> advertising does not endorse, nor imply endorsement of, any products or
> services by the Drug Information Association. Neither Custom Briefings nor
> the Drug Information Association is liable for the use of or reliance on any
> information contained in this briefing.
>
> This copy of DIA Daily was sent to maciag at post.harvard.edu courtesy of
> DIA. View Custom Briefings' privacy policy<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=037-8fc&t=c>.
>
>
> If you would like more information about, or have a question pertaining to,
> DIA Membership and its benefits, please email membership at diahome.org. Click
> here <https://www.diahome.org/DIAHOME/MyDIA/MyDIA.aspx> to check your
> membership status.
>
> Drug Information Association<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=038-a6c&t=c>| 800 Enterprise Road, Suite 200 | Horsham, PA 19044
>
> Copyright © 2011 by Custom Briefings<http://mailview.custombriefings.com/mailview.aspx?m=2011040101dia&r=5157798-812e&l=039-972&t=c>| 11190 Sunrise Valley Drive, Suite 130 | Reston, VA 20191
>

 --
Go to http://groups.google.com/group/uaem-cc to customize your message
delivery options.



-- 
------
Rachel Kiddell-Monroe
President of the Board
Universities Allied for Essential Medicines
www.essentialmedicine.org



More information about the Ip-health mailing list